Xiaoshi Jianwei Powder Veterinary Grade API is supplied as a multi-component botanical active pharmaceutical ingredient for further processing into tablets, injections, capsules, powders, granules, premixes, and solutions. The material identity is specified by the manufacturer as the monographic name, without an additional numeric model suffix; batch traceability is maintained through the certificate of analysis and the production batch number. The product is not a finished veterinary drug and is not sold as a sterile API. It is a bulk active ingredient for licensed veterinary product manufacture and pharmaceutical compounding. The API is milled and sieved to a controlled particle-size distribution, with representative release limits for loss on drying ≤ 6.0%, total ash ≤ 7.0%, acid-insoluble ash ≤ 2.0%, arsenic ≤ 2 mg/kg, lead ≤ 5 mg/kg, cadmium ≤ 1 mg/kg, and mercury ≤ 0.1 mg/kg when tested under the methods referenced in the current Chinese Veterinary Pharmacopoeia or equivalent validated procedures. Non-sterile oral-grade material is released to a total aerobic microbial count ≤ 10,000 CFU/g, combined yeast and mould count ≤ 100 CFU/g, absence of Escherichia coli in 1 g, and absence of Salmonella in 10 g. For injectable or solution applications, these limits are tightened and the material is subjected to additional bacterial endotoxin and particulate matter controls.

What Distinguishes a Multi-Dosage-Form Veterinary API from Single-Dosage-Form Powders?

Unlike single-entity synthetic actives that are released on a single assay value, Xiaoshi Jianwei Powder Veterinary Grade API is standardized through a multi-marker HPLC fingerprint. The chromatographic profile is compared against a reference standard under high-performance liquid chromatography with diode-array detection; batch acceptance requires a similarity index not less than 0.90. Thin-layer chromatography is used for identity confirmation of the major botanical components, and marker content is quantified by HPLC with UV detection according to the applicable veterinary pharmacopoeial monograph. This fingerprint-based release strategy differentiates the product from commodity herbal powders that are sold only on appearance, sieve fraction, and loss on drying. Single-dosage-form powders commonly lack the particle-size control and microbial limits required for direct compression or aseptic processing; the veterinary-grade API is produced under a quality system aligned with ICH Q7 and current good manufacturing practice for active pharmaceutical ingredients. Batch-to-batch blending is used to reduce botanical variability. The resulting material is therefore qualified for multiple downstream routes, but each route requires separate process validation because the API is not a ready-to-use finished dosage form.

Batch-to-batch variance in multi-source botanical materials is addressed by fingerprint-based blending. Raw materials from different harvest origins are analysed for marker content and heavy metals before blending; the blend ratio is adjusted to maintain the HPLC fingerprint similarity above 0.90. This is a material difference from single-component synthetic veterinary APIs, which are typically adjusted only by assay and moisture. The presence of multiple botanical constituents also means that dissolution behaviour cannot be predicted from a single solubility parameter. Formulators must evaluate the water-soluble extractive matter and the insoluble residue fraction as part of dosage-form development. The API is supplied with a certificate of analysis that includes the extraction ratio and the marker profile rather than a single assay result.

Specifications and Analytical Release Parameters

Release specifications are established in the batch-specific certificate of analysis and are verified using the general methods of the Chinese Veterinary Pharmacopoeia. The table summarises representative limits for the oral-grade non-sterile API; injectable and solution grades require additional testing for bacterial endotoxins and sub-visible particulate matter under USP <788> or corresponding pharmacopoeial chapter.

When Tablet, Capsule, and Premix Manufacture Places Different Demands on Flow and Compaction

Direct compression requires sufficient flow under gravity and resistance to segregation in the feed frame. The API is typically milled through a hammer mill fitted with a 0.5 mm screen and passed through a vibrating sieve to remove oversized material. The resulting powder has a bulk density commonly observed in the range of 0.45 g/cm³ to 0.65 g/cm³; batch-specific values are reported on the certificate of analysis. Flow function is assessed by angle of repose and compressibility index. If the angle of repose exceeds 40°, the material is not suitable for high-speed tablet press feed without a glidant such as colloidal silicon dioxide at 0.5 wt% to 1.0 wt%. Tablet manufacture is performed on rotary tablet presses with compression force in the range of 10 kN to 20 kN depending on tablet hardness and diameter.

During direct compression trials on a rotary tablet press with 16 stations and a maximum precompression force of 8 kN, the powder may exhibit sticking at relative humidity above 60% because the botanical matrix contains hygroscopic oligosaccharides. Pre-drying in a vacuum dryer at 40 °C to 50 °C for 4 h to 6 h is therefore applied when the starting loss on drying exceeds 5.0%. Magnesium stearate is added at 0.25 wt% to 0.5 wt% only after all other excipients have been blended, because extended mixing can reduce tablet hardness. The ejection force is monitored during compression; sustained ejection forces above 2,500 N indicate insufficient lubrication and require adjustment of the lubricant level or moisture content.

Capsule filling with dosator or tamping-pin machines requires D90 not more than 125 µm to avoid powder bridging and variable fill weight. On a tamping-pin capsule filler operating at 3,000 capsules per hour, weight variation is controlled within ±5% for capsules above 300 mg fill weight. Premix applications are less sensitive to flow but require homogeneous distribution; a ribbon blender or double-cone blender is used for 20 min to 30 min after geometric dilutions, and blend uniformity is confirmed by sampling at 10 points with acceptance limits of 90% to 110% of target assay.

Injectable and solution preparations require a different control state than oral solid dosage forms. The API as supplied is non-sterile; therefore, finished-product manufacturing must incorporate sterilisation by filtration or terminal sterilisation only after compatibility and stability studies. In water-based solutions, the powder is dispersed under high-shear mixing at 10,000 rpm to 15,000 rpm for 10 min, followed by clarification through a 0.45 µm prefilter and sterilising-grade 0.22 µm membrane. Sub-visible particulate matter is controlled according to USP <788> or the corresponding Chinese Veterinary Pharmacopoeia chapter, with the finished injection required to meet the specified light obscuration particle counts. Bacterial endotoxin limits are assigned at the finished-product level based on the maximum dose per animal species; for products intended for intravenous administration, the European Pharmacopoeia threshold of 5 EU/kg body mass per hour is applied unless a stricter species-specific limit is defined. Terminal sterilisation by autoclave at 121 °C for 15 min may degrade heat-labile marker components and is not recommended without a thermal stability study; published stability data for this specific botanical matrix under saturated steam conditions is limited. Non-aqueous solutions and co-solvent systems require compatibility assessment because botanical polysaccharides and tannins can precipitate at low pH or in the presence of high concentrations of cationic polymers.

Evaluating Granulation and Powder Blending Behavior

Wet granulation is preferred when the API is formulated into high-dose tablets or granules because it improves density and reduces dusting. The granulation process uses a fluid-bed granulator with inlet air temperature controlled at 60 °C to 70 °C and atomising air pressure 1.5 bar to 2.0 bar. Binder solution is typically prepared with polyvinylpyrrolidone K30 at 2 wt% to 5 wt% in purified water; ethanol may be added to control wet mass consistency, but residual solvent must be monitored under ICH Q3C. The wet granules are dried until loss on drying is below 3.0%, then sieved through a 1.0 mm mesh. Dry granulation by roller compaction is used when moisture-sensitive components are present; the roller compactor is operated at specific roll pressure, but published parameters for this specific multi-component botanical API are limited and must be established during process validation.

Fluid-bed drying curves show a constant-rate drying phase followed by a falling-rate phase; inlet air dew point is maintained below 10 °C to prevent surface crust formation. The atomising air flow rate is set at 20 L/min to 30 L/min for a 5 kg batch, but scale-up to production requires geometric similarity of the nozzle and distributor plate. Oversized granules are milled through a conical mill with round-hole screen 1.0 mm at impeller speed 1,000 rpm; fines below 75 µm are recycled into the granulation liquid to avoid dust and blend segregation. Granules intended for sachets and soluble powders are controlled for dissolution or dispersibility in water at 25 °C; complete passage through a 0.5 mm sieve is not sufficient to ensure uniform dispersion if insoluble botanical residues exceed 5% of the dry mass.

For solutions and injectable liquids, the critical difference from ordinary oral powders is not only particle size but also water-soluble fraction and electrolyte tolerance. The API contains a mixture of water-soluble and water-insoluble botanical constituents; the soluble fraction is extracted in the finished product process by controlled heating and mechanical dispersion. Filtration through a 0.22 µm membrane requires a pre-filtration step because the crude dispersion can block membranes rapidly if the D90 exceeds 50 µm after hydration. This operational boundary is not addressed by single-dosage-form powder specifications and is a key reason why oral-grade material cannot simply be dissolved in water for injection without process development. For non-aqueous solutions, co-solvent systems containing propylene glycol and glycerol are tested for osmolality and pH. The botanical extract can form precipitates when pH falls below 3.5, which requires buffering with citrate or phosphate salts; compatibility with aluminium-based adjuvants is not assumed and must be assessed because tannins can chelate trivalent metal ions. Filtration studies with a 0.45 µm polyvinylidene fluoride membrane require a depth filter when the insoluble residue after dispersion exceeds 5.0% of dry mass. The use of sterilising-grade filters with a pore size of 0.22 µm is validated by bacterial retention testing per ASTM F838-20.

What Regulatory and GMP Boundaries Apply to Veterinary Premix and Solution Applications?

The API is intended for use in veterinary medicinal products and is manufactured under a quality management system that references ISO 9001:2015, ICH Q7, and current good manufacturing practice for veterinary medicinal products. For premixes intended for incorporation into feed, homogeneity and carryover limits must be validated according to the relevant national feed regulations; batch release includes a cross-contamination risk assessment. Premix applications require a risk assessment for carryover into non-target feed; cleaning validation uses swab and rinse sampling with acceptance limits calculated under EMA/CVMP/187/2010 or the applicable national guideline. Homogeneity is assessed using a minimum of 10 sampling points across the mixer discharge, and the coefficient of variation for marker content is maintained below 5.0%. The product is not approved as a sterile API; any terminal sterilisation or aseptic processing step is the responsibility of the finished-product manufacturer.

Residual solvents are controlled to ICH Q3C options for Class 3 solvents when ethanol or other processing aids are used in granulation. Stability of the API in primary packaging is monitored under 25 °C/60% RH long-term and 40 °C/75% RH accelerated conditions according to VICH GL3; the recommended re-test period is assigned from the resulting data. Open containers should be re-sealed under nitrogen or dry air when ambient relative humidity exceeds 60%, because the botanical matrix is hygroscopic and can absorb moisture that alters flow and microbial quality. Dry blending with strong oxidising agents such as potassium permanganate should be avoided, and prolonged contact with iron, copper, or aluminium containers is not recommended because polyphenolic constituents can form dark-coloured coordination complexes.